Bypassing agent regimens and costs for prophylaxis in patients with inhibitors

被引：0
|
作者：
Gringeri, A. [1 ,2 ]
机构：
[1] IRCCS Maggiore Policlin, Dept Med & Med Special, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, Regina Elena Hosp Fdn, I-20122 Milan, Italy
[2] Univ Milan, Milan, Italy
来源：
HAEMOPHILIA | 2009年 / 15卷 / 06期
关键词：
HEMOPHILIA-A;
D O I：
10.1111/j.1365-2516.2009.02068.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1337
页数：2
相关论文
共 50 条
  • [31] Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors
    Furukawa, Shoko
    Nogami, Keiji
    Shimonishi, Naruto
    Nakajima, Yuto
    Matsumoto, Taisei
    Shima, Midori
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (05) : 727 - 735
  • [32] Bypassing Agents and Risk of Thromboembolic Events in Patients with Hemophilia and Inhibitors
    Bykov, Katsiaryna
    Bohn, Rhonda L.
    Ewenstein, Bruce M.
    Avorn, Jerry
    Seeger, John D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 468 - 469
  • [33] COST ANALYSIS OF BYPASSING AGENT PROPHYLAXIS TREATMENT VERSUS ON-DEMAND THERAPY IN HEMOPHILIA A WITH INHIBITOR IN SPAIN
    Villarrubia, R.
    Oyagueez, I
    Alvarez, M. T.
    Mingot, E.
    Parra, R.
    Casado, M. A.
    VALUE IN HEALTH, 2013, 16 (07) : A380 - A380
  • [34] A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand
    Mehta, Darshan A.
    Oladapo, Abiola O.
    Epstein, Joshua D.
    Novack, Aaron R.
    Neufeld, Ellis J.
    Hay, Joel W.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02): : 149 - U155
  • [35] FEIBA prophylaxis for patients with haemophilia and inhibitors
    Valentino, L. A.
    HAEMOPHILIA, 2006, 12 : 26 - 31
  • [36] RFVIIA PROPHYLAXIS IN HEMOPHILIA PATIENTS WITH INHIBITORS
    Torres, O. W.
    Scoles, G.
    Paoloski, G.
    Pollola, J.
    Ferro, A. M.
    Buceta, A.
    Cermelj, M.
    VOX SANGUINIS, 2010, 99 : 502 - 502
  • [37] Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors
    Schreuder, Mark
    Verhoef, Daniel
    Cheung, Ka Lei
    Visscher, Koen
    Geerke, Daan
    Reitsma, Pieter H.
    Bos, Mettine H. A.
    BLOOD, 2017, 130
  • [38] Thromboelastography as a global assay to monitor bypassing agents in hemophilia patients with inhibitors
    Santoro, C.
    Jacobson, L.
    Wang, M.
    Manco-Johnson, M. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 945 - 945
  • [39] Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors
    Tran, H. T. T.
    Sorensen, B.
    Rea, C. J.
    Bjornsen, S.
    Ueland, T.
    Pripp, A. H.
    Tjonnfjord, G. E.
    Holme, P. A.
    HAEMOPHILIA, 2014, 20 (03) : 369 - 375
  • [40] Zymogen-like FXa Is a Potent Bypassing Agent for Reversal of Direct FXa Inhibitors in Vivo
    Thalji, Nabil K.
    Ivanciu, Lacramioara
    Jasuja, Reema
    Patel-Hett, Sunita
    Fruebis, Joachim
    Pittman, Debra
    Camire, Rodney M.
    BLOOD, 2014, 124 (21)
12345